Compare Stocks: DAWN, TGTX, ABVX, and PCVX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$90.68 -1.2%	$113.28	$69.81 ▼ $148.83	$7.92B	1.14	1.43 million shs	740,448 shs
DAWN Day One Biopharmaceuticals	$21.53	$19.41	$5.64 ▼ $21.53	$2.22B	-1.74	1.52 million shs	2.99 million shs
PCVX Vaxcyte	$66.50 -9.9%	$59.04	$39.87 ▼ $90.75	$10.02B	1.23	1.47 million shs	3.50 million shs
TGTX TG Therapeutics	$52.80 -2.1%	$53.67	$26.76 ▼ $59.30	$8.09B	1.8	2.16 million shs	959,594 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	-1.24%	-5.29%	-20.09%	-35.48%	+9.31%
DAWN Day One Biopharmaceuticals	0.00%	0.00%	0.00%	0.00%	+170.82%
PCVX Vaxcyte	+30.70%	+26.69%	+20.70%	+21.67%	+73.04%
TGTX TG Therapeutics	-0.70%	-4.06%	-3.71%	-7.15%	+46.85%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$90.68 -1.2%	$113.28	$69.81 ▼ $148.83	$7.92B	1.14	1.43 million shs	740,448 shs
DAWN Day One Biopharmaceuticals	$21.53	$19.41	$5.64 ▼ $21.53	$2.22B	-1.74	1.52 million shs	2.99 million shs
PCVX Vaxcyte	$66.50 -9.9%	$59.04	$39.87 ▼ $90.75	$10.02B	1.23	1.47 million shs	3.50 million shs
TGTX TG Therapeutics	$52.80 -2.1%	$53.67	$26.76 ▼ $59.30	$8.09B	1.8	2.16 million shs	959,594 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	-1.24%	-5.29%	-20.09%	-35.48%	+9.31%
DAWN Day One Biopharmaceuticals	0.00%	0.00%	0.00%	0.00%	+170.82%
PCVX Vaxcyte	+30.70%	+26.69%	+20.70%	+21.67%	+73.04%
TGTX TG Therapeutics	-0.70%	-4.06%	-3.71%	-7.15%	+46.85%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVX Abivax	2.88	Moderate Buy	$156.69	72.81% Upside
DAWN Day One Biopharmaceuticals	2.00	Hold	$23.29	8.15% Upside
PCVX Vaxcyte	2.63	Moderate Buy	$108.60	63.31% Upside
TGTX TG Therapeutics	2.44	Hold	$63.00	19.33% Upside

Current Analyst Ratings Breakdown

Latest DAWN, TGTX, ABVX, and PCVX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/5/2026	PCVX Vaxcyte	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$116.00 ➝ $125.00
10/5/2026	PCVX Vaxcyte	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$89.00
10/5/2026	PCVX Vaxcyte	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$110.00 ➝ $122.00
10/2/2026	PCVX Vaxcyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/28/2026	PCVX Vaxcyte	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$133.00 ➝ $130.00
9/25/2026	PCVX Vaxcyte	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$110.00
9/22/2026	ABVX Abivax	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$155.00 ➝ $151.00
9/22/2026	ABVX Abivax	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$140.00 ➝ $118.00
9/22/2026	ABVX Abivax	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$148.00
9/21/2026	TGTX TG Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
9/9/2026	ABVX Abivax	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$155.00

(Data available from 10/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVX Abivax	N/A	N/A	N/A	N/A	$6.57 per share	N/A
DAWN Day One Biopharmaceuticals	$158.18M	14.06	N/A	N/A	$4.30 per share	5.01
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$20.51 per share	N/A
TGTX TG Therapeutics	$799.54M	10.11	$2.72 per share	19.38	$4.08 per share	12.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVX Abivax	-$380.27M	-$6.06	N/A	N/A	N/A	N/A	-91.69%	-71.96%	12/21/2026 (Estimated)
DAWN Day One Biopharmaceuticals	-$107.32M	-$1.03	N/A	2,153.00	N/A	-67.85%	-23.43%	-20.69%	N/A
PCVX Vaxcyte	-$766.63M	-$7.63	N/A	N/A	N/A	N/A	-37.56%	-33.62%	11/3/2026 (Estimated)
TGTX TG Therapeutics	$447.18M	$2.74	19.29	19.92	2.33	55.22%	73.49%	34.14%	11/2/2026 (Estimated)

Latest DAWN, TGTX, ABVX, and PCVX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	PCVX Vaxcyte	-$2.1189	N/A	N/A	N/A	$12.50 million	N/A
11/2/2026	Q3 2026	TGTX TG Therapeutics	$0.36	N/A	N/A	N/A	$245.18 million	N/A
9/21/2026	Q2 2026	ABVX Abivax	-$0.9170	-$1.71	-$0.7930	-$1.68	$0.80 million	$1.37 million
8/5/2026	Q2 2026	PCVX Vaxcyte	-$2.06	-$1.97	+$0.09	-$1.97	$12.50 million	N/A
8/3/2026	Q2 2026	TGTX TG Therapeutics	$0.3057	$0.05	-$0.2557	$0.05	$229.77 million	$240.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVX Abivax	N/A	N/A	N/A	N/A	N/A
DAWN Day One Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVX Abivax	N/A	5.97	5.97
DAWN Day One Biopharmaceuticals	N/A	8.02	7.91
PCVX Vaxcyte	N/A	5.72	5.72
TGTX TG Therapeutics	1.23	4.27	3.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVX Abivax	47.91%
DAWN Day One Biopharmaceuticals	87.95%
PCVX Vaxcyte	96.78%
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
ABVX Abivax	N/A
DAWN Day One Biopharmaceuticals	6.20%
PCVX Vaxcyte	3.30%
TGTX TG Therapeutics	8.87%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVX Abivax	80	87.35 million	N/A	Not Optionable
DAWN Day One Biopharmaceuticals	60	103.33 million	96.93 million	Optionable
PCVX Vaxcyte	507	148.81 million	143.89 million	Optionable
TGTX TG Therapeutics	399	153.07 million	139.49 million	Optionable

DAWN, TGTX, ABVX, and PCVX Headlines

Recent News About These Companies

TG Therapeutics (NASDAQ:TGTX) Stock Breaks Above 200-Day Moving Average - Here's What Happened

October 6 at 3:21 AM | americanbankingnews.com

TG Therapeutics (NASDAQ:TGTX) Shares Break Above 200 Day Moving Average - Should You Sell?

October 6 at 3:19 AM | marketbeat.com

Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm

September 28, 2026 | prnewswire.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Stock Has Average Target Price of $63.00

September 27, 2026 | americanbankingnews.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of "Hold" from Analysts

September 27, 2026 | marketbeat.com

Head-To-Head Comparison: Puma Biotechnology (NASDAQ:PBYI) & TG Therapeutics (NASDAQ:TGTX)

September 26, 2026 | americanbankingnews.com

TG Therapeutics Inc (TGTX)

September 24, 2026 | ru.investing.com

Dow Jones futures fall after Nasdaq hits new high; SanDisk, Micron trigger buy signals

September 23, 2026 | msn.com

Dow Jones futures: Nasdaq hits new high; SanDisk, Micron trigger buy signals

September 22, 2026 | msn.com

Bank of America Corp DE Acquires Shares of 1,309,788 TG Therapeutics, Inc. $TGTX

September 20, 2026 | marketbeat.com

Tidal Investments LLC Buys New Holdings in TG Therapeutics, Inc. $TGTX

September 19, 2026 | marketbeat.com

TG Therapeutics (TGTX) Could Be 19% Undervalued After Its Recent Rebound

September 18, 2026 | finance.yahoo.com

TG Therapeutics Eyes $1B Run Rate as BRIUMVI Gains MS Market Share

September 18, 2026 | marketbeat.com

TG Therapeutics (NASDAQ:TGTX) Trading 8.3% Higher - Here's Why

September 16, 2026 | marketbeat.com

TG Therapeutics (NASDAQ:TGTX) Director Sells 5,000 Shares

September 15, 2026 | insidertrades.com

TG Therapeutics, Inc. $TGTX Shares Sold by WINTON GROUP Ltd

September 15, 2026 | marketbeat.com

California State Teachers Retirement System Has $9.37 Million Stock Position in TG Therapeutics, Inc. $TGTX

September 15, 2026 | marketbeat.com

TG Therapeutics (NASDAQ:TGTX) Director Sells $274,800.00 in Stock

September 14, 2026 | marketbeat.com

Hsbc Holdings PLC Has $884,000 Holdings in TG Therapeutics, Inc. $TGTX

September 14, 2026 | marketbeat.com

VIRGINIA RETIREMENT SYSTEMS ET Al Invests $2.17 Million in TG Therapeutics, Inc. $TGTX

September 11, 2026 | marketbeat.com

TG Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

September 10, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

DAWN, TGTX, ABVX, and PCVX Company Descriptions

Abivax NASDAQ:ABVX

$90.68 -1.06 (-1.15%)

As of 11:48 AM Eastern

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Day One Biopharmaceuticals NASDAQ:DAWN

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Vaxcyte NASDAQ:PCVX

$66.50 -7.32 (-9.91%)

As of 11:48 AM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

TG Therapeutics NASDAQ:TGTX

$52.80 -1.11 (-2.07%)

As of 11:48 AM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DAWN, TGTX, ABVX, and PCVX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DAWN, TGTX, ABVX, and PCVX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DAWN, TGTX, ABVX, and PCVX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DAWN, TGTX, ABVX, and PCVX Company Descriptions

Abivax NASDAQ:ABVX

Day One Biopharmaceuticals NASDAQ:DAWN

Vaxcyte NASDAQ:PCVX

TG Therapeutics NASDAQ:TGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DAWN, TGTX, ABVX, and PCVX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DAWN, TGTX, ABVX, and PCVX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DAWN, TGTX, ABVX, and PCVX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DAWN, TGTX, ABVX, and PCVX Company Descriptions

Abivax NASDAQ:ABVX

Day One Biopharmaceuticals NASDAQ:DAWN

Vaxcyte NASDAQ:PCVX

TG Therapeutics NASDAQ:TGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools